Expert Opinion on Therapeutic Targets最新文献_第4页

New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand? 动脉粥样硬化中降脂和抗炎疗法的新目标和作用机制：该领域的现状如何？

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-05-01 Epub Date: 2024-06-04 DOI: 10.1080/14728222.2024.2362644

Stephen J Nicholls, Adam J Nelson

{"title":"New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?","authors":"Stephen J Nicholls, Adam J Nelson","doi":"10.1080/14728222.2024.2362644","DOIUrl":"10.1080/14728222.2024.2362644","url":null,"abstract":"Introduction: Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality worldwide, despite widespread use of statins. There is a need to develop additional therapeutic strategies that will complement statins to achieve more effective reductions in cardiovascular risk.Areas covered: This review provides a comprehensive summary of current areas of therapeutic development targeting both lipid and inflammatory factors implicated in the pathogenesis of atherosclerosis. In addition to develop of novel approaches that will produce more effective lowering of low-density lipoprotein cholesterol, clinical trials are currently evaluating the potential to target other atherogenic lipid parameters such as triglyceride-rich lipoproteins and Lp(a), in addition to promoting the biological properties of high-density lipoproteins. Targeting inflammation within the vascular wall has emerged as a new frontier in cardiovascular prevention, with early evidence that use of anti-inflammatory agents have the potential to reduce cardiovascular risk.Expert opinion: Clinical practice has an increasing array of therapeutic tools to achieve more effective lowering of low-density lipoprotein cholesterol for high-risk patients. In addition, clinical trials have the potential to deliver a range of additional agents to the clinic, that target alternative lipid and inflammatory mediators. This will permit the potential to personalize cardiovascular prevention.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Candidate molecular targets uncovered in mouse lifespan extension studies. 小鼠寿命延长研究中发现的候选分子靶标

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-24 DOI: 10.1080/14728222.2024.2346597

Maria Vedunova, Olga Borysova, Georgiy Kozlov, Anna-Maria Zharova, Ivan Morgunov, A. Moskalev

{"title":"Candidate molecular targets uncovered in mouse lifespan extension studies.","authors":"Maria Vedunova, Olga Borysova, Georgiy Kozlov, Anna-Maria Zharova, Ivan Morgunov, A. Moskalev","doi":"10.1080/14728222.2024.2346597","DOIUrl":"https://doi.org/10.1080/14728222.2024.2346597","url":null,"abstract":"INTRODUCTION\u0000Multiple interventions have demonstrated an increase in mouse lifespan. However, non-standardized controls, sex or strain-specific factors, and insufficient focus on targets, hinder the translation of these findings into clinical applications.\u0000\u0000\u0000AREAS COVERED\u0000We examined the effects of genetic and drug-based interventions on mice from databases DrugAge, GenAge, the Mouse Phenome Database, and publications from PubMed that led to a lifespan extension of more than 10%, identifying specific molecular targets that were manipulated to achieve the maximum lifespan in mice. Subsequently, we characterized 10 molecular targets influenced by these interventions, with particular attention given to clinical trials and potential indications for each.\u0000\u0000\u0000EXPERT OPINION\u0000To increase the translational potential of mice life-extension studies to clinical research several factors are crucial: standardization of mice lifespan research approaches, the development of clear criteria for control and experimental groups, the establishment of criteria for potential geroprotectors, and focusing on targets and their clinical application. Pinpointing the targets affected by geroprotectors helps in understanding species-specific differences and identifying potential side effects, ensuring the safety and effectiveness of clinical trials. Additionally, target review facilitates the optimization of treatment protocols and the evaluation of the clinical feasibility of translating research findings into practical therapies for humans.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140663933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Arenobufagin induces cell apoptosis by modulating the cell cycle regulator claspin and the JNK pathway in nasopharyngeal carcinoma cells. 阿瑞诺布法金通过调节鼻咽癌细胞的细胞周期调节因子Caspin和JNK通路诱导细胞凋亡

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-24 DOI: 10.1080/14728222.2024.2348014

Hsin-Yu Ho, Mu-Kuan Chen, Chia-Chieh Lin, Yu‐Sheng Lo, Yi‐Ching Chuang, Ming-Ju Hsieh

{"title":"Arenobufagin induces cell apoptosis by modulating the cell cycle regulator claspin and the JNK pathway in nasopharyngeal carcinoma cells.","authors":"Hsin-Yu Ho, Mu-Kuan Chen, Chia-Chieh Lin, Yu‐Sheng Lo, Yi‐Ching Chuang, Ming-Ju Hsieh","doi":"10.1080/14728222.2024.2348014","DOIUrl":"https://doi.org/10.1080/14728222.2024.2348014","url":null,"abstract":"BACKGROUND\u0000The high recurrence rate and incidence of distant metastasis of nasopharyngeal carcinoma (NPC) result in poor prognosis. Natural compounds that can complement combination radiation therapy need to be identified. Arenobufagin is commonly used for heart diseases and liver cancer, but its effectiveness in NPC is unclear.\u0000\u0000\u0000STUDY DESIGN AND METHODS\u0000The effect of arenobufagin-induced apoptosis was measured by a cell viability assay, tumorigenic assay, fluorescence assay, and Western blot assay through NPC-039 and NPC-BM cell lines. The protease array, Western blot assay, and transient transfection were used to investigate the underlying mechanism of arenobufagin-induced apoptosis. A NPC xenograft model was established to explore the antitumor activity of arenobufagin in vivo.\u0000\u0000\u0000RESULTS\u0000Our findings indicated that arenobufagin exerted cytotoxic effects on NPC cells, inhibiting proliferation through apoptosis activation. The downregulation of claspin was confirmed in arenobufagin-induced apoptosis. The combined treatment of arenobufagin and inhibitors of mitogen-activated protein kinase demonstrated that arenobufagin induced NPC apoptosis through the c-Jun N-terminal kinases (JNK) pathway inhibition. Furthermore, arenobufagin suppressed NPC tumor proliferation in vivo.\u0000\u0000\u0000CONCLUSION\u0000Our results revealed the antitumor effect of arenobufagin in vitro and in vivo. Arenobufagin may provide clinical utility on NPC due to the suppression of claspin and the JNK pathway.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140661042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting PRL phosphatases in hematological malignancies. 针对血液恶性肿瘤中的 PRL 磷酸酶。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-23 DOI: 10.1080/14728222.2024.2344695

Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Z. Zhang, Yan Liu

{"title":"Targeting PRL phosphatases in hematological malignancies.","authors":"Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Z. Zhang, Yan Liu","doi":"10.1080/14728222.2024.2344695","DOIUrl":"https://doi.org/10.1080/14728222.2024.2344695","url":null,"abstract":"INTRODUCTION\u0000Phosphatase of regenerating liver (PRL) family proteins, also known as protein tyrosine phosphatase 4A (PTP4A), have been implicated in many types of cancers. The PRL family of phosphatases consists of three members, PRL1, PRL2, and PRL3. PRLs have been shown to harbor oncogenic potentials and are highly expressed in a variety of cancers. Given their roles in cancer progression and metastasis, PRLs are potential targets for anticancer therapies. However, additional studies are needed to be performed to fully understand the roles of PRLs in blood cancers.\u0000\u0000\u0000AREAS COVERED\u0000In this review, we will summarize recent studies of PRLs in normal and malignant hematopoiesis, the role of PRLs in regulating various signaling pathways, and the therapeutic potentials of targeting PRLs in hematological malignancies. We will also discuss how to improve current PRL inhibitors for cancer treatment.\u0000\u0000\u0000EXPERT OPINION\u0000Although PRL inhibitors show promising therapeutic effects in preclinical studies of different types of cancers, moving PRL inhibitors from bench to bedside is still challenging. More potent and selective PRL inhibitors are needed to target PRLs in hematological malignancies and improve treatment outcomes.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140668659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress. 目前针对癌症 HPK1 的策略以及临床前研究进展的障碍。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-22 DOI: 10.1080/14728222.2024.2344697

Hui Chen, Xiangna Guan, Chi He, Tingting Lu, Xingyu Lin, Xuebin Liao

{"title":"Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress.","authors":"Hui Chen, Xiangna Guan, Chi He, Tingting Lu, Xingyu Lin, Xuebin Liao","doi":"10.1080/14728222.2024.2344697","DOIUrl":"https://doi.org/10.1080/14728222.2024.2344697","url":null,"abstract":"INTRODUCTION\u0000Hematopoietic progenitor kinase 1 (HPK1), a 97-kDa serine/threonine Ste20-related protein kinase, functions as an intracellular negative regulator, primarily in hematopoietic lineage cells, where it regulates T cells, B cells, dendritic cells and other immune cells. Loss of HPK1 kinase activity results in exacerbated cytokine secretion, enhanced T cell signaling, improved viral clearance, and thus increased restraint of tumor growth. These findings highlight HPK1 as a promising target for immuno-oncology treatments, culminating in the advancement of candidate compounds targeting HPK1 to clinical trials by several biotech enterprises.\u0000\u0000\u0000AREAS COVERED\u0000Through searching PubMed, Espacenet-patent search, and clinicaltrials.gov, this review provides a comprehensive analysis of HPK1, encompassing its structure and roles in various downstream signaling pathways, the consequences of constitutive activation of HPK1, and potential therapeutic strategies to treat HPK1-driven malignancies. Moreover, the review outlines the patents issued for small molecule inhibitors and clinical investigations of HPK1.\u0000\u0000\u0000EXPERT OPINION\u0000To enhance the success of tumor immunotherapy in clinical trials, it is important to develop protein degraders, allosteric inhibitors, and antibody-drug conjugates based on the crystal structure of HPK1, and to explore combination therapy approaches. Although several challenges remain, development of HPK1 inhibitors display promising in preclinical and clinical studies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140673835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical and immunological features of alopecia areata following SARS-CoV-2 infection or COVID-19 vaccines. 感染 SARS-CoV-2 或接种 COVID-19 疫苗后出现的斑秃的临床和免疫学特征。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-22 DOI: 10.1080/14728222.2024.2344696

Shiqi Fu, Xiuzu Song

引用次数: 0

Strategies and techniques for preclinical therapeutic targeting of PI3Kin oncology: where do we stand in 2024? 以 PI3Kin 为靶点的肿瘤临床前治疗策略和技术：2024 年我们将何去何从？

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-22 DOI: 10.1080/14728222.2024.2342522

Yanyan Liu, Qiu Sun, Xiawei Wei

引用次数: 0

S100A1: a promising therapeutic target for heart failure S100A1：有望治疗心力衰竭的靶点

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-19 DOI: 10.1080/14728222.2024.2345746

Dorothea Noll, Dorothea Kehr, Patrick Most, Julia Ritterhoff

引用次数: 0

Molecular drilling to combat salmonella typhi biofilm using L-Asparaginase via multiple targeting process 利用 L-天冬酰胺酶通过多重靶向过程对抗伤寒沙门氏菌生物膜的分子钻研

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-19 DOI: 10.1080/14728222.2024.2344699

Aditya Upadhyay, Dharm Pal, Awanish Kumar

引用次数: 0

Role of Non-receptor tyrosine kinases in epilepsy: significance and potential as therapeutic targets 非受体酪氨酸激酶在癫痫中的作用：作为治疗靶点的意义和潜力

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-17 DOI: 10.1080/14728222.2024.2343952

Ozasvi R Shanker, Sonali Kumar, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit

引用次数: 0